- Trial phase
- Preclinical / Early-stage (no confirmed Phase 1/2 clinical trials identified)
- Time to market
- Not stated
- Why 2/10
- VK3019 is an early-stage/preclinical asset with no scheduled near-term binary catalyst (no PDUFA, no confirmed Phase 2/3 readout) in the next 12 months. The company's value is dominated by its lead asset VK2735 (Phase 3 obesity), making VK3019 a minor pipeline component. ImpactScore is 2 per the rubric for a preclinical/minor program with no scheduled catalyst.
VK3019 is preclinical/early-stage and not the company's primary value driver, investors should watch Viking's lead asset VK2735 (Phase 3 obesity) for near-term stock movement. VK3019 updates would most likely come via Viking's R&D day or quarterly earnings calls. The next company catalyst is Q3 2026 earnings on October 28, 2026, where pipeline updates on both VK2735 and VK3019 may be discussed.
Price Chart
Executive Summary
VK3019 is an amylin agonist being developed by Viking Therapeutics (NASDAQ: VKTX) for the treatment of obesity and metabolic disorders. It is an early-stage/preclinical asset, the second pipeline program behind the company's lead drug VK2735 (a GLP-1/GIP dual agonist already in Phase 3 trials). In September 2026, Viking raised approximately $534 million through a combined stock and convertible note offering, specifically earmarking proceeds to fund both VK2735 commercialization and VK3019 advancement. VK3019 has no upcoming near-term binary catalyst (no PDUFA date, no confirmed Phase 2/3 readout), and the company's stock value is currently dominated by VK2735's Phase 3 obesity program. Analyst consensus on VKTX is Strong Buy with a mean price target of ~$95, but the stock has declined to ~$24.40 after the dilutive capital raise.
How It Works
VK3019 is an amylin agonist, a drug that mimics the natural hormone amylin, which is co-secreted with insulin after meals. Amylin slows gastric emptying (makes food leave the stomach more slowly), promotes a feeling of fullness (satiety), and helps regulate blood sugar. The mechanism is complementary to GLP-1 agonists like Ozempic/Wegovy, while GLP-1 drugs boost insulin secretion, amylin agonists target different satiety pathways, potentially offering additive weight loss or better tolerability when combined.
Trial Status
VK3019 is an early-stage development program. No specific clinical trial data appears in public registries/updates. The SEC filing from September 2026 states that capital raised will fund "continued clinical development" of VK2735 and "advancement" of VK3019, suggesting the program has not yet entered pivotal-stage clinical trials. The company's lead program VK2735 (oral formulation) initiated Phase 3 trials (SUNRISE-1 and SUNRISE-2) in October 2026.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings call (October 28, 2026), possible pipeline update on VK3019
- Any early clinical data readout for VK3019 (no date confirmed)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Viking Therapeutics, Inc PRESS-RELEASE VKTX ·Originating report